An update on the pharmacotherapy options for pediatric diabetes (Q38175521)

30 August 2017

An update on the pharmacotherapy options for pediatric diabetes (English)

1 reference

30 August 2017

0 references

M Loredana Marcovecchio

series ordinal

1

1 reference

PubMed ID

24387753

30 August 2017

Francesco Chiarelli

series ordinal

2

1 reference

PubMed ID

24387753

30 August 2017

language of work or name

English

0 references

publication date

6 January 2014

1 reference

Expert Opinion on Biological Therapy

30 August 2017

1 reference

30 August 2017

14

1 reference

30 August 2017

355-364

1 reference

30 August 2017

3

1 reference

Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study

30 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Type 2 diabetes in youth: epidemiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Type 2 diabetes in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Global trends in the incidence and prevalence of type 2 diabetes in children and adolescents: a systematic review and evaluation of methodological approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Insulin treatment in children and adolescents with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidore study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

The Past 200 Years in Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Treatment options for paediatric diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Clinical experience with insulin glargine in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

The metabolic and mitogenic properties of basal insulin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Insulin detemir: a review of its use in the management of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Treatment of type 1 diabetes in children and adolescents using modern insulin pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Closed-loop insulin delivery: from bench to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Artificial pancreas: past, present, future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Closed-loop insulin delivery for treatment of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Hypoglycaemia and counterregulation during childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Insulin treatment in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Potential role of non-insulin adjunct therapy in Type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

The use of metformin in type 1 diabetes: a systematic review of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Does metformin improve vascular health in children with type 1 diabetes? Protocol for a one year, double blind, randomised, placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Liraglutide as additional treatment for type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

The role of adjunctive exenatide therapy in pediatric type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

GAD treatment and insulin secretion in recent-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Blockade of interleukin 1 in type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Treatment of type 2 diabetes in youth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Type 2 diabetes in pediatrics and adults: thoughts from a clinical pharmacology perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Management of newly diagnosed type 2 Diabetes Mellitus (T2DM) in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Type 2 diabetes in children and adolescents in a 2-year follow-up: insufficient adherence to diabetes centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

21 January 2018

Thiazolidinedione safety

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

A review of the efficacy and safety of oral antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

A clinical trial to maintain glycemic control in youth with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.874413

10.1517/14712598.2014.874413

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24387753